Home Cart Sign in  
Chemical Structure| 148081-72-5 Chemical Structure| 148081-72-5

Structure of HTHQ
CAS No.: 148081-72-5

Chemical Structure| 148081-72-5

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

HTHQ, which is a hydroquinone monoalkyl ether, is a potent anti-oxidative agent, even at low dose levels.

Synonyms: HX-1171; 1-O-hexyl-2,3,5-trimethylhydroquinone; BTT-105

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of HTHQ

CAS No. :148081-72-5
Formula : C15H24O2
M.W : 236.35
SMILES Code : OC1=C(C)C=C(OCCCCCC)C(C)=C1C
Synonyms :
HX-1171; 1-O-hexyl-2,3,5-trimethylhydroquinone; BTT-105
MDL No. :MFCD00797612
InChI Key :ATMNQRRJNBCQJO-UHFFFAOYSA-N
Pubchem ID :119193

Safety of HTHQ

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
PC12 cells 10 μM 6 hours HTHQ significantly reduced L-DOPA-induced p38MAPK and JNK1/2 phosphorylation. PMC6429301
PC12 cells 10 μM 24 hours HTHQ significantly reduced L-DOPA-induced cleaved caspase-3 expression. PMC6429301
PC12 cells 10 μM 2 hours HTHQ restored L-DOPA-reduced Bad phosphorylation and decreased Bax expression. PMC6429301
PC12 cells 50 μmol/L or less 3 hours To evaluate the protective effects of HTHQ on H/R-induced oxidative stress and apoptosis. Results showed that HTHQ treatment significantly restored SOD, CAT, and GSH activities, decreased MDA content, and reduced apoptosis. PMC7521305
PC12 cells 1, 10, 100 μM 24 hours HTHQ significantly attenuated L-DOPA-induced cell viability reduction and inhibited SOD activity reduction. PMC6429301
Human umbilical vein endothelial cells (HUVECs) 5, 25, 50 μM 6 hours HTHQ treatment significantly attenuated oxidative stress and endothelial cell apoptosis following H/R by activating the Nrf2/HO-1 pathway. PMC7840260

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
F344 male rats Rat multi-organ carcinogenesis model Diet 0.0025 28 weeks To evaluate the inhibitory effect of HTHQ on carcinogenesis induced by AP and NaNO2. Results showed that HTHQ significantly reduced the incidences of hepatocellular adenomas and hemangiosarcomas. PMC5926933
C57BL/6J mice Middle cerebral artery occlusion (MCAO) model Oral 100 or 200 mg/kg Three consecutive days, once daily To evaluate the protective effects of HTHQ on cerebral ischemia/reperfusion injury. Results showed that HTHQ treatment significantly reduced infarct volume, neurological deficit scores, brain water content, oxidative stress, and neuronal apoptosis. PMC7521305
Wistar rats Parkinson's disease model Intraperitoneal injection 25 mg/kg and 50 mg/kg Once daily for 10 days HTHQ, with its antioxidant attributes, reduced the levels of 8-isoprostane, lipid oxidation products, and protein oxidation products. The decrease in oxidative stress due to HTHQ led to a reduction in the mRNA content of proinflammatory cytokines and myeloperoxidase activity, accompanying the drop in the expression of the factor NF-κB. These alterations promoted an improvement in motor coordination scores and increased tyrosine hydroxylase levels, whereas histopathological changes in the brain tissue of the experimental animals were attenuated. HTHQ exhibited greater effectiveness than the comparative drug rasagiline based on the majority of variables. PMC10528003
Male SD rats Dimethylnitrosamine (DMN)-induced liver fibrosis model Oral 50, 100, 200 mg/kg Once daily for 4 weeks To evaluate the inhibitory effect of HTHQ on DMN-induced liver fibrosis. Results showed that HTHQ significantly improved relative liver weight and serum chemistry levels, reduced hydroxyproline and malondialdehyde levels in the liver, decreased mRNA levels of PDGF, α-SMA, and TGF-β, and reduced fibrotic septa formation. PMC3834479
Male F344 rats ENUR-pretreated rat model Dietary administration 1.0%, 0.5%, 0.25%, 0.125% HTHQ 36 weeks To evaluate the promoting effect of HTHQ on the development of forestomach and tongue tumors in ENUR-pretreated rats. Results showed that HTHQ significantly promoted forestomach carcinogenesis at the 0.25% dose, while its effect on tongue carcinogenesis was weak. PMC5921845
C57BL/6 mice Preeclampsia (PE) model Oral 100 or 200 mg/kg Once daily from gestation day 0.5 to day 17.5 HTHQ treatment significantly alleviated high systolic blood pressure (SBP) and proteinuria, increased fetal weight and fetal weight/placenta weight ratio, and inhibited oxidative stress and endothelial cell apoptosis by activating the Nrf2/HO-1 pathway in preeclamptic mice. PMC7840260

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT01548391 Healthy PHASE1 UNKNOWN - Asan Medical Center, Seoul, Ko... More >>rea, Republic of Less <<
NCT01889745 Healthy TEMPORARILY_NOT_AVAILABLE - Asan Medical Center, Special C... More >>ity of Seoul, Korea, Republic of Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

4.23mL

0.85mL

0.42mL

21.16mL

4.23mL

2.12mL

42.31mL

8.46mL

4.23mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories